Search clinical trials for: custirsen (OGX-011)/mitoxantrone

Total 19 results

Achieve Life Sciences

Completed

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Prostate Cancer

Canada
Achieve Life Sciences

Completed

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada
Achieve Life Sciences

Unknown

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Taiwan, Spain, Israel, Italy, Korea, Republic of, New Zealand, Australia, Germany, United States, Hungary, Poland, Russian Federation, Singapore, Thailand, Ukraine
University of British Columbia
United States Department of Defense

Completed

Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

Prostate Cancer

Canada
Achieve Life Sciences

Completed

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

Prostate Cancer

France, United States, Canada, Australia, Hungary, Czech Republic, Russian Federation, United Kingdom
Digestome Therapeutics

Completed

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001

Depressive Disorder

Australia
REGENXBIO Inc.

Active, not recruiting

RGX-111 Gene Therapy in Patients With MPS I

Hurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)

United States, Brazil, Israel
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
Achieve Life Sciences
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)

Prostate Cancer

United States, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
Sun Pharmaceutical Industries Limited

Completed

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca | Dry Eye Disease

United States
Genexine, Inc.

Unknown

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer (GX-051)

Head and Neck Cancer

Korea, Republic of
Sun Pharmaceutical Industries Limited

Completed

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca
National Cancer Institute (NCI)

Recruiting

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Endometrial Serous Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
Sun Pharmaceutical Industries Limited

Completed

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (Emerald)

Keratoconjunctivitis Sicca

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage... and other conditions

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage II Vaginal Cancer AJCC v6 and v7 | Stage III Vaginal Cancer AJCC v6 and v7 | Stage IIIB Cervical... and other conditions

United States

Search clinical trials for: custirsen (OGX-011)/mitoxantrone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations